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CORRESPONDENCE
Letters to the Editor
Combination Prophylactic
Therapy for Post-Operative
Atrial Fibrillation
The incidence of atrial fibrillation (AF) after cardiac surgery is
high, and although often transient, it is associated with increased
hospital costs, length of stay, post-operative complications, and
increased short- and long-term mortality (1,2). Prophylactic strat-
egies have been shown to decrease length of hospital stay and costs
and should therefore be considered in all patients undertaking
cardiac surgery, especially those with high-risk factors (including
age, male gender, hypertension, prior history of atrial fibrillation,
and left atrial size) (2,3). Both pharmacological and nonpharma-
cological approaches to prevention have been studied and are
discussed in the recent review by Echahidi et al. (4). Several
prophylactic strategies are discussed and include use of beta-
blockers, sotalol, amiodarone, calcium-channel blockers, magne-
sium, and atrial pacing. That being said, is there any role for
combining these strategies? Echahidi et al. (4) warn that “the
concomitant use of beta-blocker drugs [with amiodarone] might
also exacerbate adverse effects [bradycardia].” However, a random-
ized, double-blinded, placebo-controlled trial of 253 patients
without significant left ventricular dysfunction (average age 65 
11 years) showed that the combination of amiodarone and meto-
prolol was more effective than metoprolol alone in the prevention
of post-operative atrial fibrillation (5). Furthermore, bradycardia
necessitating dose reduction or drug withdrawal was not increased
in the amiodarone plus metoprolol combination. Bradycardia
occurred in 3.1%, 3.2%, 12.7%, and 16.1% in the placebo,
amiodarone and metoprolol combination (combined amiodarone
and metoprolol; p  0.65 vs. placebo), sotalol (sotalol vs. placebo;
p  0.05), and in the metoprolol groups, respectively (metoprolol
vs. placebo; p  0.05). Another randomized trial enrolled 207
consecutive coronary artery bypass patients (mean age 62  11
years) with an ejection fraction 0.40 to receive either sotalol
alone, magnesium alone, both agents, or no antiarrhythmic agents
(6). The incidence of post-operative AF was 38% in the control
group, 11.8% in the sotalol group, 14.8% in the patients receiving
only magnesium, and only 1.9% in those receiving both sotalol and
magnesium. Statistically significant differences in the incidences of
post-operative AF were found when groups were compared in this
study. Therefore, a combined prophylactic strategy in some pa-
tients might dwarf the effects of either agent alone and might not
necessarily result in increased side effects.
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Reply
We thank Dr. Kapoor for raising the point that a combination
therapy might be a very effective and safe strategy to prevent the
occurrence of post-operative atrial fibrillation (POAF). It is generally
well accepted that, in absence of contraindication, beta-blocker drugs
should be started early after the operation to prevent POAF (1). The
relevance of the addition of other pharmacologic agents to prevent the
occurrence of POAFmust be evaluated in light of the patient’s clinical
characteristics and risk-to-benefit ratio. In this regard, a prophylactic
therapy must be efficient and have a low risk of drug-related adverse
effect. Combination therapies including either a beta-blocker plus
amiodarone or sotalol with magnesium have been documented to be
efficient with a low rate of drug-related adverse event (2,3). Surpris-
ingly, in 1 randomized study, combination of metoprolol and amio-
darone was not associated with more bradycardia than the placebo,
whereas administration of metoprolol alone increased the risk of this
complication (2). It remains uncertain whether these results were
merely explained by chance alone or by other unknown mechanisms.
Sotalol is associated with a higher incidence of symptomatic
bradycardia, which might necessitate drug withdrawal. Amioda-
rone has a well-documented toxicity including among other things
sinus bradycardia (4), and combination of this drug with beta-
blockers has been reported to increase the risk of symptomatic
bradycardia (5). Whether combining amiodarone and beta-
blockers might attenuate or avoid the side effects of each of the 2
drugs used alone remains uncertain and controversial. Hence
prophylactic therapy for POAF should be tailored to the individual
baseline characteristics and post-operative evolution of each pa-
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tient to maximize the efficiency of the therapy without inducing
adverse effects.
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